ClinicalTrials.gg
CompletedNCT06301971Updated May 2, 2024

A Study to Assess Mass Balance, Pharmacokinetics, Metabolism, and Excretion of Emraclidine in Healthy Adult Male Participants

A Phase 1 interventional study of Emraclidine in Healthy Participants, sponsored by Cerevel Therapeutics, LLC. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-02.

Sponsored by Cerevel Therapeutics, LLC (part of AbbVie) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2024, 2 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The primary purpose of this study is to determine the mass balance, routes, and rates of elimination of total radioactivity and characterize the pharmacokinetics (PK) of emraclidine, metabolite CV-0000364, and total radioactivity in plasma and whole blood following a single oral dose of [14C]-emraclidine in healthy adult male participants.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Cerevel Therapeutics, LLC is the lead sponsor of 22 studies on the registry; none are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 1 (5%) have results posted.

First submitted before Cerevel Therapeutics, LLC became part of AbbVie.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (BMI) of 18.5 to 35.0 kilograms per square meters (kg/m\^2), inclusive, and a total body weight ≥50 kg [110 Pounds (lbs)].
  2. A male participant who is sexually active with a pregnant or a nonpregnant woman of must agree to use a condom during the trial and for 90 days after the dose of medicinal product (IMP). In addition, male participants should not donate sperm for a minimum of 90 days following the dose of IMP.
  3. Ability, in the opinion of the investigator, to understand the nature of the trial and comply with protocol requirements, including the prescribed dosage regimens, scheduled visits, laboratory tests, and other trial procedures.
  4. Capable of consuming the standard diet.
  5. History of a minimum of 1 bowel movement per day.

Exclusion criteria

Exclusion Criteria:

  1. Current or past history of significant cardiovascular, pulmonary, gastrointestinal, renal, hepatic, metabolic, genitourinary, endocrine (including diabetes mellitus, thyroid disorders), , hematological, immunological, neurological, or psychiatric disease that, in the opinion of the investigator or medical monitor, could compromise either participant safety or the results of the trial.
  2. "Yes" responses for any of the following items on the C-SSRS (within the individual's lifetime):

    • Suicidal Ideation Item 3 (Active Suicidal Ideation with Any Methods [Not Plan] without Intent to Act)
    • Suicidal Ideation Item 4 (Active Suicidal Ideation with Some Intent to Act, without Specific Plan)
    • Suicidal Ideation Item 5 (Active Suicidal Ideation with Specific Plan and Intent)
    • Any of the Suicidal Behavior items (Actual Attempt, Interrupted Attempt, Aborted Attempt, Preparatory Acts or Behavior)

    "Yes" responses for any of the following items on the C-SSRS (within past 12 months):

    • Suicidal Ideation Item 1 (Wish to be Dead)
    • Suicidal Ideation Item 2 (Non-Specific Active Suicidal Thoughts) Serious risk of suicide in the opinion of the investigator is also exclusionary.
  3. Any condition or surgery that could possibly affect drug absorption, including, but not limited to, bowel resections, bariatric weight loss surgery/procedures, gastrectomy, and cholecystectomy.
  4. Use of any prescription and over-the-counter medications from 28 days prior to first dose of IMP or likely to require concomitant therapy. Vaccinations or boosters within 28 days of planned dosing or while on trial.
  5. Positive result for (HIV) antibody, surface antigen, hepatitis B total core antibody, or antibody with detectable viral ribonucleic acid (RNA) levels at Screening.
  6. Positive drug screen (including cotinine and tetrahydrocannabinol [THC]) or a positive test for alcohol.
  7. Any of the following clinical laboratory test results at the Screening Visit or Check-in (Day -1), which can be confirmed by a single repeat measurement, if deemed necessary:

    • (AST) or alanine aminotransferase (ALT) ≥2× (ULN).
    • Total ≥1.5×ULN. If Gilbert's syndrome is suspected, total bilirubin ≥1.5×ULN is acceptable if the conjugated or direct bilirubin fraction is \<20% of total bilirubin.
  8. Known allergy or to the IMP, closely related compounds, or any of their specified ingredients.

NOTE: Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Emraclidine 30 mg

    Participants will receive a single oral dose of 30 milligrams (mg) (approximately 75 microcurie \[μCi\]) \[14C\]-emraclidine on Day 1.

    Drug: Emraclidine

Interventions

  • Oral solution/suspension

    Also known as: CVL-231

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration Time Curve (AUC) from Zero to Infinity (AUCinf) of Emraclidine, its Metabolite CV-0000364 and Total Radioactivity in Plasma and Whole Blood

    Time frame: Pre-dose and at multiple time points post-dose up to Day 15

  2. AUC from Time 0 to last Quantifiable Concentration (AUClast) of Emraclidine, its Metabolite CV-0000364 and Total Radioactivity in Plasma and Whole Blood

    Time frame: Pre-dose and at multiple time points post-dose up to Day 15

  3. Maximum Plasma Concentration (Cmax) of Emraclidine, its Metabolite CV-0000364 and Total Radioactivity in Plasma and Whole Blood

    Time frame: Pre-dose and at multiple time points post-dose up to Day 15

  4. Time to Last Measurable Concentration (Tlast) of Emraclidine, its Metabolite CV-0000364 and Total Radioactivity in Plasma and Whole Blood

    Time frame: Pre-dose and at multiple time points post-dose up to Day 15

  5. Time to Maximum Observed Concentration (Tmax) of Emraclidine, its Metabolite CV-0000364 and Total Radioactivity in Plasma and Whole Blood

    Time frame: Pre-dose and at multiple time points post-dose up to Day 15

  6. Apparent Terminal Elimination Half-life (t½) of Emraclidine, its Metabolite CV-0000364 and Total Radioactivity in Plasma and Whole Blood

    Time frame: Pre-dose and at multiple time points post-dose up to Day 15

  7. Terminal Rate Constant (λz) of Emraclidine, its Metabolite CV-0000364 and Total Radioactivity in Plasma and Whole Blood

    Time frame: Pre-dose and at multiple time points post-dose up to Day 15

  8. Total Plasma Clearance After Oral Administration (CL/F) of Emraclidine

    Time frame: Pre-dose and at multiple time points post-dose up to Day 15

  9. Apparent Volume of Distribution During the Terminal Phase (Vz/F) of Emraclidine

    Time frame: Pre-dose and at multiple time points post-dose up to Day 15

  10. Ratio of Plasma AUCinf for Emraclidine to Plasma AUCinf for Total Radioactivity

    Time frame: Pre-dose and at multiple time points post-dose up to Day 15

  11. Ratio of Plasma AUCinf for Metabolite CV-0000364 to Plasma AUCinf for Total Radioactivity

    Time frame: Pre-dose and at multiple time points post-dose up to Day 15

  12. Ratio of Plasma AUCinf for Metabolite CV-0000364 to Plasma AUCinf for Emraclidine

    Time frame: Pre-dose and at multiple time points post-dose up to Day 15

  13. Ratio of Whole Blood AUCinf for Total Radioactivity to Plasma AUCinf for Total Radioactivity

    Time frame: Pre-dose and at multiple time points post-dose up to Day 15

  14. Amount Excreted in Urine (Aeu) of Total Radioactivity

    Time frame: Pre-dose and at multiple time points post-dose up to Day 15

  15. Cumulative Aeu of Total Radioactivity

    Time frame: Pre-dose and at multiple time points post-dose up to Day 15

  16. Percentage Excreted in Urine (feu) of Total Radioactivity

    Time frame: Pre-dose and at multiple time points post-dose up to Day 15

  17. Cumulative feu of Total Radioactivity

    Time frame: Pre-dose and at multiple time points post-dose up to Day 15

  18. Amount Excreted in Feces (Aef) of Total Radioactivity

    Time frame: Pre-dose and at multiple time points post-dose up to Day 15

  19. Cumulative Aef of Total Radioactivity

    Time frame: Pre-dose and at multiple time points post-dose up to Day 15

  20. Percentage Excreted in Feces (fef) of Total Radioactivity

    Time frame: Pre-dose and at multiple time points post-dose up to Day 15

  21. Cumulative fef of Total Radioactivity

    Time frame: Pre-dose and at multiple time points post-dose up to Day 15

  22. Percentage Dose (%Dose) of Total Radioactivity Excreted in Urine Plus Feces Combined

    Time frame: Pre-dose and at multiple time points post-dose up to Day 15

  23. Cumulative Percentage Dose of Total Radioactivity Excreted in Urine Plus Feces Combined

    Time frame: Pre-dose and at multiple time points post-dose up to Day 15

Secondary outcomes

  1. Metabolite Profile of Emraclidine in Plasma, Urine and Feces

    Time frame: Pre-dose and at multiple time points post-dose up to Day 15

  2. Structural Identification of Emraclidine Metabolites Found in Plasma, Urine and Feces

    Time frame: Pre-dose and at multiple time points post-dose up to Day 15

  3. Number of Participants with Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to Day 16

  4. Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) Values

    Time frame: Up to Day 15

  5. Number of Participants with Clinically Significant Changes in Vital Signs

    Time frame: Up to Day 15

  6. Number of Participants with Clinically Significant Changes in Laboratory Assessments

    Time frame: Up to Day 15

  7. Number of Participants with Clinically Significant Changes in Physical and Neurological Examination Results

    Time frame: Up to Day 15

  8. Change from Baseline in Columbia Suicide Severity Rating Scale (C-SSRS) Score

    The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present (from 1 to 5, with 5 being the most severe). Greater lethality or potential lethality of suicidal behaviors (endorsed on the behavior subscale) indicates increased risk.

    Time frame: Up to Day 15

07

Study locations

1 site
  • Austin, Texas
    Austin, Texas 78744, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2024 to primary completion in Apr 2024, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2024
First posted
Mar 8, 2024
StartActual
Mar 4, 2024
Primary completionActual
Apr 4, 2024
CompletionActual
Apr 4, 2024
Last update
May 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06301971
Responsible party
Sponsor
First posted
Mar 8, 2024
Start date
Mar 4, 2024
Primary completion
Apr 4, 2024
Completion
Apr 4, 2024
Last update
May 2, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emraclidine

Start the discussion